Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-04-29 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2021-04-29 English
NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT
Foreign Filer Report
2021-04-26 English
TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION
Foreign Filer Report
2021-04-26 English
SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1
Foreign Filer Report
2021-04-26 English
Selumetinib recommended for EU approval in NF1
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 5117W' and is dated April 26, 2021. It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the recommendation for marketing authorisation of a drug (Selumetinib) in the EU. The text is a formal press release style announcement containing clinical trial results and company commentary. Crucially, it is distributed via RNS, the news service of the London Stock Exchange, and contains standard RNS footer information. This type of announcement, which is a formal regulatory disclosure but not a comprehensive financial report (like 10-K or IR) or a specific corporate action notice (like DIV or SHA), fits best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes. Given the context of a major regulatory milestone announcement distributed through the official exchange mechanism, RNS is the most appropriate classification.
2021-04-26 English
Tagrisso adjuvant receives positive CHMP opinion
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and is dated April 26, 2021. It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorisation of Tagrisso in the EU, based on Phase III trial results. This is a specific, time-sensitive announcement of a regulatory/clinical development milestone, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is a formal announcement distributed via the RNS system, and it details a specific regulatory event (CHMP recommendation), it fits best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard announcement, although it is highly specific. Given the options, RNS serves as the best fit for a general regulatory news release that isn't a standard financial report or a specific insider/dividend announcement.
2021-04-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.